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Abstract
Background: The chemicals of metabolism are constructed of a small set of atoms and bonds. This may be because
chemical structures outside the chemical space in which life operates are incompatible with biochemistry, or because
mechanisms to make or utilize such excluded structures has not evolved. In this paper I address the extent to which
biochemistry is restricted to a small fraction of the chemical space of possible chemicals, a restricted subset that I call
Biochemical Space. I explore evidence that this restriction is at least in part due to selection again specific structures,
and suggest a mechanism by which this occurs.
Results: Chemicals that contain structures that our outside Biochemical Space (UnBiological groups) are more likely to
be toxic to a wide range of organisms, even though they have no specifically toxic groups and no obvious mechanism
of toxicity. This correlation of UnBiological with toxicity is stronger for low potency (millimolar) toxins. I relate this to the
observation that most chemicals interact with many biological structures at low millimolar toxicity. I hypothesise that
life has to select its components not only to have a specific set of functions but also to avoid interactions with all the
other components of life that might degrade their function.
Conclusions: The chemistry of life has to form a dense, self-consistent network of chemical structures, and cannot
easily be arbitrarily extended. The toxicity of arbitrary chemicals is a reflection of the disruption to that network
occasioned by trying to insert a chemical into it without also selecting all the other components to tolerate that
chemical. This suggests new ways to test for the toxicity of chemicals, and that engineering organisms to make high
concentrations of materials such as chemical precursors or fuels may require more substantial engineering than just of
the synthetic pathways involved.
Keywords: Toxicity, Metabolic network, Protein structure, Ecotoxicology, Protein binding, Non-specific binding,
Xenobiotic
Background
The biochemistry we observe in life on Earth is an island
in the chemical space of possible biochemistry. Not all
possible small organic molecules are made by life, and the
chemicals making up the metabolic pathways common to
life are limited to a small number of classes of chemicals –
aldehydes, polyols, amines, alpha amino acids etc.. Under-
standing why biochemistry uses the molecules that it does
is central both to engineering biochemistry to produce
useful products and to understanding how terrestrial bio-
chemistry originated. Is the restriction on the observed
chemistry of life simply because life has not evolved the
catalysts needed to make other molecules, because life has
not found a need for them, or because there is selection
against chemistry outside ‘biochemical space’?
It is plausible to suggest that life simply has not invented
the means to make some classes of chemicals. We know
that life makes carbon-carbon bonds using aldol conden-
sation and not (for example) metathesis [1, 2], although
metathesis enzymes can be designed in principle [3].
There may simply not be any functional reason for making
some molecules driving the evolution of the relevant
enzymatic mechanisms.
There may also be limits on what biochemistry can
achieve outside those imposed by catalytic mechanisms
and the function of metabolites. For example, it has pre-
viously been shown that a simple measure of the degree
of saturation of a molecule may be used to indicate that
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molecule’s toxicity, in the absence of any other struc-
tural information about the molecule, a finding that is
related to the distribution of biochemicals in chemical
space [4]. It would be surprising if this were the only
such constraint on the molecules of life.
In this paper I present evidence that there is selection
against the incorporation of chemicals that contain struc-
tural features not found in central metabolism – chemi-
cals that I term ‘Unbiological’ – into metabolism, separate
from the constraints provided by selection for specific
function and the ability of life to catalyse specific types of
reaction. Specifically, the sections below argue that:
i) the chemical space of the biochemicals that are
common to life on Earth is a small subset of the
chemical space possible to the chemistry of life
('Biochemistry occupies a limited chemical
space').
ii) that chemicals outside biochemical space have a
higher chance of being toxic at millimolar
concentrations than chemicals that fall inside
biochemical space ('Mild toxicity is correlated with
‘UnBiological’ chemical characteristics' thru
'Threshold for correlations is millimolar
concentration').
iii) that a wide range of experimental data suggests that
many small molecules bind to many proteins with low
millimolar affinity, which provides a mechanism for
the toxicity of chemicals at millimolar concentrations
('Mechanism of Ub correlation with toxicity')
iv) that the reason for correlation of the toxicity of
chemicals and their distance from biochemistry is
that life has systematically evolved proteins to
avoid unwanted millimolar interactions with
metabolites in order to avoid poisoning itself
('Proposed mechanism of correlation of Ub with
millimolar toxicity').
The results in the paper are in two parts to reflect this
reasoning. The Results and discussion sections (Figs. 2, 4
and 5) describes the chemical space of life and the low level
toxicity of chemicals falling outside this space. The sections
on Mechanism of Ub correlation with toxicity and Pro-
posed mechanism of correlation of Ub with millimolar tox-
icity (Figs. 6 and 7) provides an explanation for this effect.
These results suggest that biochemistry is more of an
integrated whole than the conventional metabolic map
would suggest. This has theoretical and practical impli-
cations, which I discuss briefly at the end of the paper.
Results and discussion
Biochemistry occupies a limited chemical space
I first establish that biochemical space is a relatively
small subset of the possible chemical space from which
metabolism could be selected. It is a commonplace that
many of the components of primary metabolism “look
similar to each other” (as undergraduates learning how
to distinguish the α-amino acids or the sugars of the
Calvin Cycle can attest). This section establishes that
this apparent limitation of metabolism to a few chem-
ical types is a real restriction in chemical space.
The chemical space from which metabolism is selected
is the space of chemicals made from C, N, O, and H,
with S as S(II) and P(V), bonded in ways that are found
in biological molecules. For example, 2-amino-4-hydro-
xyhexanoate looks like a plausible amino acids, but it
happens not be made by life,1 whereas ACCA (Fig. 1)
does not fit an intuitive feeling of what a biochemical
looks like, as few biological compounds contain a cyclobu-
tane ring. Of the myriad compounds that can be formed
from the elements C, N, O, P and S (and H), life rarely
forms hydrazines, peroxides, rings of less than five atoms,
or phosphorus compounds other than phosphates.
These rules, and some others relating to molecular
stability, were implemented in the program Combimol
as previously described [5]. The chemical space of pos-
sible biochemicals includes structures usually excluded
from drug design due to their sensitivity to metabolism
[6]. From the chemical space of all such molecules, all
Fragments were generated as described in [7, 8]. This
provides a library of Substructures with which to probe
the space of actual molecules that make up metabolism.
Life’s metabolic diversity is enormous [9]. For the pur-
poses of this paper, I use a small subset of metabolites that
are components of the central metabolic processes of all
life on Earth, and pragmatically those processes that are
shown on the Roche/Expasy metabolic map [10]. All the
small molecules listed in Part 1 (“Metabolic Pathways”)
were used as a set of metabolites here called “core metab-
olism”, a collection of 611 molecules widely used by all life
on Earth (some steroid hormones were not used, as they
are chemically very similar and so contribute no new
chemical structural types to the data set).
There are more Fragments of 5, 6 and 7 atoms than
there are metabolites in core metabolism, so we would
expect that some of them would not be represented in
that metabolism. The chances that a 5-atom Fragment
will be a substructure of a molecule depends on the size
of the molecule. Figure 2a shows the expected fraction
of those Fragments that would not be found in a set of
611 molecules if the molecules were constructed ran-
domly from the atoms and bonds found in core metab-
olism. (The algorithm used to estimate the frequency
with which a Fragment will match a molecule selected at
random from the space of chemicals is described in more
detail in Appendix 1.) Fig. 2a shows that the expected
number of Fragments that are not found is substantially
smaller than the actual number: core metabolism must
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represent a small subset of the chemical space of possible
water-stable chemicals that can be made from C, N,
O S(II) and P (V). Figure 2b extends this analysis to
the ~45,000 natural product chemicals in the Dictionary
of Natural Products (DNP - [11]). DNP records the
detection and structural analysis of organic chemicals
from any natural source, and so samples the full di-
versity of chemistry of terrestrial life. If terrestrial
biochemistry sampled all the chemical space of
CHON, S(II) and P(V) chemistry, then essentially all
of the Fragments searched here should be represented
in the database. However over 50 % of 6-atom
Fragments are not found in the database.
Why is biochemistry apparently limited to a subset
of the possible chemistry that life could perform? The
next three sections demonstrates that chemicals that
fall outside the chemical space occupied by bio-
chemistry are not merely unlikely to be part of a
metabolism, but interfere with that metabolism in a
way as to produce a toxic effect, and the further
outside ‘biochemical space’ they are, the greater that
antagonism.
Mild toxicity is correlated with ‘UnBiological’ chemical
characteristics
In this section I introduce a measure of how different a
chemical is from the chemical space of life. I show that a
greater difference is correlated with low levels of non-
specific toxicity. Toxicity is related to the existence of
structures in the test chemical that are different from
chemical structures usually found in biology.
Chemicals can be toxic for one of three broad reasons.
Toxic chemicals can be chemically reactive, such as
formaldehyde or mercury compounds, and so chemically
modify the components of life. Reactive toxicity depends
on specific chemical functionality. The Combimol chem-
ical generation software automatically excludes reactive
moieties, and so this is not a class of toxicity probed by
these studies.
Toxic chemicals can interact with a specific molecular
mechanism in the organism, and so disrupt a particular bio-
chemical function (see discussion in [12–17]). Drugs and
plant secondary metabolite toxins achieve their effect
in this way. This is caused by very specific chemical
structures, which confer specific toxicity on molecules
Fig. 2 Extent of biochemical space. Fraction (Y axis) of Fragments derived from the space of all possible chemicals that are not found in actual
metabolites, compared to the fraction that would be expected not to be found in the same number of chemicals sampled at random from the
chemical space of possible metabolites, plotted as a function of fragment size (N – X axis). Blue squares – fraction of fragments not found in
actual metabolites. Red circles – fraction not found in an equivalent size collection of random molecules. Panel a: fragments not found in the
‘core metabolism’ of 611 molecules represented in the ExPasy metabolic map. Panel b: Fragments not found in the ~45,000 unique molecules
listed in the Dictionary of Natural Products [11]
Fig. 1 Examples of non-metabolites
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that contain them. Such ‘structural alerts’ were origin-
ally identified to predict mutagenicity [18], but have
been extended to more general toxicity prediction in
programs such as DEREK [19], TOPKAT, MULTI-
CASE [20] and others [21]. In my terms, a ‘structural
alert’ is a Fragment that has a high affinity for a specific
molecular target whose blockade produces a toxic effect.
In agreement with this, ‘structural alert’ approaches to tox-
icity prediction or other structure-activity relationship
methods that try to relate large structural features to bio-
logical endpoints work well for specific toxicity mecha-
nisms, such as HERG blockade giving rise to cardiac
toxicity [7] or electrophilic attack on DNA giving rise to
carcinogenicity [18].
Structural alert approaches do not work well for pre-
dicting broad toxicity endpoints, such as death [22]. A
wide range of industrial chemicals have, or are claimed
to have, toxicity that is not severe or life-threatening at
low concentrations, and which is not obviously linked to
structural alerts, but which nevertheless cause morbidity
and mortality in model organisms at higher concentra-
tions. Interactions of some of these chemicals with
various receptors or enzymes is claimed, but most are
simply observed to disable or kill model species without
a mechanism for their toxicity being known or postu-
lated. It is this third class of low potency, non-specific
toxicity that I have probed further below.
I use a Fragment-based approach to identify the largest
part of a molecule which is different from anything found
in biology. Fragment-based methods of describing mole-
cules are well known, computationally simple approaches
to describing a molecule in terms of how its structure
would be drawn by a chemist [23]. Several groups have
described using a fragment-based approach for molecular
description and design [24–26], claiming that building
drug-like molecules from chemical fragments derived
from biochemicals lead to more ‘drug-like’ results.
I define a measure of the fraction of a molecule
that is not similar to a biological molecule, which I
call “UnBiological” (Ub). Ub is defined as the largest re-
gion of a test molecule that does not overlap with at least
one molecule in the core metabolite set. Ub has to be de-
fined in terms of the size of the Fragments used to deter-
mine overlaps. Because the difference between the
expected and observed occupancy of chemical space
shown in Fig. 2 is greatest for 5-atom and 6-atom
Fragments, 5-atom and 6-atom overlaps were both used
for this study, designated as Ub5 and Ub6 respectively.
The algorithm used to generate the Ub measures is
summarised in the Methods section, with more detail
on the actual computational steps used in Appendix 2,
and a graphic summary of the process in Fig. 3.
In Table 1 I show the result of correlating the values
of Ub calculated for each chemical species with the
toxicity endpoints measured for that chemical species,
for a variety of measures of general, non-specific toxicity.
As is standard in toxicology, the measure of toxicity
is the logarithm of the concentration that gives a
half-maximal toxic effect in the system under consid-
eration. Log (concentration) scales are commonly
used in biochemistry because of the linear relation-
ship between the binding energy of a small molecule
binding to a large one and the logarithm of the
equilibrium constant of that binding. Pragmatically, a
log scale also enables visualization of data spanning many
orders of magnitude. The half-maximal affect (EC50 or
LD50) is the commonly reported value for many toxico-
logical and pharmacological measures. In the case where
the effect is causes by simple binding to a single target, a
half-maximal effect represents the concentration at which
the target is 50 % occupied, i.e. the Kd.
Here the Ub measure (i.e. how much of a molecule
does not match a structure found in core metabolism) is
negatively correlated with the logarithm of the concen-
tration at which a chemical has a half-maximal effect.
This might be LD50 for a lethal toxicity measure or EC50
for a non-lethal measure. A negative value of the correl-
ation means that a larger Ub is associated with a lower
concentration, i.e. with a more potent toxin.
In almost all cases, for Ub5 and Ub6, there is a signifi-
cant negative correlation between Ub and toxic concen-
tration. For a wide range of living systems, from isolated
mammalian cells through unicellular plants and protests
to multicellular plants and diverse animal species, Ub is
correlated with toxicity. This correlation is highly statis-
tically significant. The “***” level of significance in Table 1
is an indication of p < 0.000714 that the indicated correl-
ation will be produced by chance. There were around 70
correlations performed for this initial analysis of the data
(35 data sets, including two not shown sub-dividing the
rat and mouse data into pharmacological categories,
which had little effect, correlated with 2 Ub endpoints).
If Ub was uncorrelated with toxicity, there is only a p = 0.05
chance that we would observe one “***” level correlation in
this data set.
The one exception to the pattern of correlation of Ub
with toxicity is Saccharomyces cereviseae, which shows
only weak correlation between the toxicity endpoints
reported here and Ub5 or Ub6. A possible reason for this
will be discussed below in the section on thresholds for
correlations.
I emphasize what this does and does not show. The
correlations show robustly that molecules with seg-
ments that are not represented in the chemicals of core
metabolism have a higher chance of being toxic at any
given concentration level than molecules made up of
structures found in core metabolism. The larger that
“UnBiological” segment is, the more toxic the molecule
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is. None of the molecules tested for toxicity here are
normal components of central metabolism (arguably
with the exception of ethanol).
However this is not a method for detecting or predict-
ing pharmacology mediated by a single, known target, or
for detecting or predicting toxicity based on a single
mechanism. The effects being detected here are rela-
tively non-specific: while many of the toxins are known
to interact with proteins, they typically interact with
many proteins, and toxic effects often cannot be attrib-
uted to a specific molecular interaction. This is illus-
trated by the exploratory analysis in Table 2. Table 2
shows the result of correlating UnBiological with three
conventional toxicity endpoints and two pharmaco-
logical ones. HERG toxicity is a significant risk factor for
cardiac toxicity in pre-clinical drug candidates, and is
detected by screening for blockade of the HERG ion
channel in cells [7, 27]. Oestrogenic potential is a
common ecotoxicological toxicity measure, and is mea-
sured here by binding to the oestrogen receptor [28].
Tadpole narcosis is a whole organism measure of both
Central Nervous System penetration and effect on a
select set of neurotransmitter receptors [29]. All three
are therefore mechanism-based measures of toxicity, and
all three show weaker correlations with Ub6 and no
correlation with Ub5. An initial statistical analysis of the
distribution of Ub5 and Ub6 in the molecules used for
the analyses in Tables 3 and 4 (see Appendix 3) suggests
that the molecules analysed for Tadpole Narcosis may be
atypical of the other sets in the study, and so the lack of
correlation found between Ub5 and Tadpole narcosis
may be a result of an unrepresentative set of chemicals.
The other sets of chemicals whose analysis is summa-
rized in Table 4 appear similar in overall Ub5 and
Ub6 properties to those whose analysis is summarized
in Table 3.
Fig. 3 Cartoon of calculating UnBiological (Ub). This takes a ‘toy domain’ of four metabolites and three target molecules to explain the process.
Only fragments of 3 or 4 atoms are considered in this example. In reality there are 611 metabolites, ~5000 targets molecules (note that a number
of molecules are tested in more than one experimental series in Table 3) and 30912 Fragments of size 3 to 14 atoms. Metabolites and target
molecules are used to generate Fragments that are present in at least two of the overall set of molecules (This is a convenient limitation
on the number of Fragments, and may be revised in future implementations of the algorithm). Fragments are classified as to whether they
occur in the set of metabolites (green) or do not occur in metabolites (red). The target set of molecules is then matched to the set of Fragments
that do not occur in metabolites – the size of the largest such Fragment is the Ub measure. Note that in this simplified model it is clear that the
presence of a chlorine atom confers ‘UnBiological-ness’ on a molecule. The size of the Ub fragment can be the same as the size of the whole
molecule (e.g. 1-cloropropane in this example). As illustrated here, this approach takes no account of the potential reactivity of a molecule, only
its topological structure
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Drugs can also be toxic in the wrong place or dose. In
Table 2 I also show that Ub is uncorrelated with the
potency of compounds for just two drug targets (for
which I had data to hand), antihistamines and NSAIDs
that inhibit cycloxygenase-2. Neither show any signifi-
cant correlation with Ub.
I do not claim that other toxicity or pharmacology end-
points will not be found to correlate with UnBiological.
The examples in Table 2 are included to make the point
that Ub is correlated with broad, whole-organism toxicity,
not necessarily with target-specific mechanisms.
Reasons for variability of correlation
Table 1 provides robust statistical evidence for believing
that UnBiological is correlated with whole organism tox-
icity. However the degree of correlation varies substan-
tially between species, as does the statistical significance
of that correlation. This could be due to genuine
biological differences, or differences in the chemical
space being sampled. The issue of chemical space cover-
age is significant. For example, an initial study suggested
a strong correlation of Ub with the potency of
phosphodiesterase-4b inhibitors (data not shown). How-
ever this was based on analysis of the data in two QSAR
studies on PDE4b inhibition. The chemicals in the two
studies were very similar to each other (i.e. were two
specific series of chemicals). In effect, Ub was being used
to classify compounds into the two studies, one of which
was developing a much more potent drug series than
the other. Therefore Ub could identify more potent
PDE4b inhibitors, but for the trivial reason that it was
identifying two studies looking at two classes of chemi-
cals. When a wider set of PDE4 inhibitors was analysed,
the correlation was reduced.2 It seems likely that, as with
other QSAR methods, UnBiological will work best on a
chemical set spread uniformly across the chemical space
that is to be analysed. Bias in the molecules that happen
to have been investigated to generate the data analysed
here may be a cause of the differences in correlation of
Ub and toxicity. This can only be addressed by collecting
a more systematic set of multi-species toxicity data on
defined chemicals. Data filed for the REACH legislation
[30] may provide such a data set in the future.
Statistical significance is a function of sample size. It is
not practical to collect hundreds of toxicity endpoints
from all the species involved, and not desirable to discard
endpoints from species that have been extensively tested.
Therefore this aspect of variability has been retained in
the study.
Threshold for correlations is millimolar concentration
Many of the correlations summarised in Table 1 are
statistically robust but relatively small. Direct plots of
Ub vs. toxicity are usually uninformative. A good and
Table 1 Correlations of Ub with toxicity endpoints
Endpoint Number Ub5 Ub6
Trout 24 h 186 −0.230** −0.337***
Trout 96 h 181 −0.419*** −0.516***
Pteronarcys (24 h) 52 −0.433** −0.385**
Pteronarcys (96 h) 52 −0.456*** −0.369**
Bluegill (24 h) 157 −0.149 −0.215**
Bluegill (96 h) 172 −0.216** −0.276***
Gammarus (24 h) 113 −0.437*** −0.208*
Gammarus (96 h) 132 −0.407*** −0.205*
Fathead minnow 578 −0.311*** −0.308***
Rat oral 814 −0.441*** −0.372***
Mouse oral 398 −0.199*** −0.191***
Rat IP 170 −0.214** −0.147
Mouse IP 290 −0.180** −0.161**
AMES (mutagenicity) 163 −0.316*** −0.518***
CPDBAS rat 519 −0.198*** −0.191***
CPDBAS mouse 402 −0.145** −0.198***
CPDBAS hamster 44 −0.430** −0.351*
Drosophila 139 −0.397*** −0.337***
Lemna - non-Herbicides 149 −0.428*** −0.502***
Lemna - Herbicides 174 −0.392*** −0.428***
Tetrahymena 334 −0.408*** −0.448***
Chlorella 91 −0.578*** −0.738***
Scenedesmus 63 −0.237 −0.467***
Yeast 253 0.095 −0.014
NCI 768 −0.113** −0.137***
Rank Correlation coefficient between toxicity endpoints and UnBiological (Ub)
measures. Two Ub measures are shown – Ub5 and Ub6, calculated from an
overlap of 5 and 6 atoms between target molecule and the pool of
metabolites. See Appendix 2 for more detailed descriptions of calculation of
Ub. Column 1: toxicity endpoint. Column 2: number of data points. Column 3
and 4: correlation of Ub5 and Ub6 respectively with appropriate toxicity endpoint.
Significance of the correlation of flagged by asterisks.* = p < 0.05.** = p < 0.01***
= p < 0.000714. Note that*** is a value selected to be 0.05/(35*2), to correct for
multiple testing of 35 toxicity endpoints and 2 correlates. If Ub5 and Ub6 were
randomly distributed with respect to toxicity, then we would expect to have to
do this study 20 times to come up with one correlation of p < 0.000714
Table 2 Correlation of Ub with other biological endpoints
Endpoint Number UB5 Ub6
HERG 229 −0.062 0.179**
Oestrogenic 131 −0.024 −0.342***
Tadpole narcosis 141 −0.043 −0.267**
COX-2 107 −0.069 −0.149
Antihistamine 61 −0.097 −0.0126
Rank correlation coefficient of three target-related toxicity measures and two
pharmacological endpoints with UnBiological measures Ub5 and Ub6. Column 1:
Pharmacological endpoint. Column 2: number of data points. Columns 3 and 4:
correlations with Ub5 and Ub6 respectively. Significance flags are the same as
in Table 1
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Table 3 Biological datasets
Data set Number of compounds Species Measured endpoint Source
Whole organism toxicity endpoints
Trout (24 h) 186 Oncorhynchus mykiss Death [111] These two data sets differ only in the
time of exposure – 1 and 3 days
Trout (96 h) 181
Pteronarcys (24 h) 52 Pteronarcys californica Death [111] These two data sets differ only in the
time of exposure – 1 and 3 days
Pteronarcys (96 h) 52
Bluegill (24 h) 157 Lepomis macrochirus Death [111] These two data sets differ only in the
time of exposure – 1 and 3 days
Bluegill (96 h) 172
Gammarus (24 h) 113 Combined data from G.
fasciatus, G. lacustris and G.
Pseudolimnaeus
Death [111] These two data sets differ only in the
time of exposure – 1 and 3 days
Gammarus (96 h) 132
Fathead minnow 578 Pimephales promelas Death [112]
Rat oral 814 Rattus norvegicus Death [113] Rodent toxicity data was manually
curated from The Merck Index.
Note that ‘molar’ values for mammalian
whole organism studies are calculated
as moles/kg body mass
Mouse oral 398 Mus musculus
Rat IP 170 Rattus norvegicus
Mouse IP 290 Mus musculus
AMES (mutagenicity) 163 Salmonella typhimurium Mutated colony formation Data collected and provided
by Choracle Ltd, derived from
Toxnet [114]
CPDBAS rat 519 Rattus norvegicus Tumour formation frequency [115]
CPDBAS mouse 402 Mus musculus
CPDBAS hamster 44 Mesocricetus auratus
Drosophila 139 Drosophila melanogaster Death [116] Only compounds with at least two
compound concentrations
reported included
Lemna - non-Herbicides 149 Lemna gibba and Lemna
minor
lack of growth/leaflet reduction [117–136] Compounds developed for reasons
other than their herbicide effect
Lemna - Herbicides 174 Lemna gibba and Lemna
minor
lack of growth/leaflet reduction [117] Compounds developed as herbicides
(primarily for macroscopic land plants)
Tetrahymena 334 Tetrahymena pyriformis Death [137–140]
Chlorella 91 Chlorella vulgaris Death [141]
Scenedesmus 63 Cell numbers (combination growth
inhibition and death)
[142–154] Data-set heavy on chlorinated and
nitrated aromatic compounds
Yeast 253 Saccharomyces cereviseae Growth inhibition [106] Mostly drug-like molecules: See













Table 3 Biological datasets (Continued)
Other endpoints
NCI 768 Homo sapiens Cell number (cell growth
vs. cell killing)
[39] Cell culture assay, not whole organism.
Cytotoxicty data from the NCI anti-HIV
compounds screening programme.
HERG 229 Homo sapiens Ion channel blockade [7] Ion channel assay in cloned receptor assay,
not whole organism test
Oestrogenic 131 Rattus norvegicus Receptor binding IC50 [155] Receptor binding assay, not a cell- or
organism-based assay
Tadpole narcosis 141 Rana temporaria Narcosis (reversible lack
of motion)
[29]
COX-2 107 N/A Cycloxygenase-2 inhibition [156]
Antihistamine 61 N/A Histamine receptor blockade [157–159] A variety of related structures, including
anti-psychotics












strong statistical correlation can be shown for data that
does not appear ‘correlated’ to the eye – this is the
reason for performing correlation calculations. However,
for some of the more strongly correlated data sets con-
taining relatively few data points, such as those plotted
in Fig. 4, the correlation between Ub and toxicity appears
stronger for weakly potent toxins than for highly po-
tent ones (i.e. the correlation is clearer on the right-
hand side of the graphs, and weak or non-existent on
the left-hand side). This has also been observed for
the correlation of structural redox with toxicity [4].
For some of the data sets there are a sufficiently large
number of data points to split the data into potency bands
and correlate these independently with UnBiological. The
results from this analysis are shown in Fig. 5. For
consistency, toxicity data was binned into bands of round
number log units of LD50 or EC50, which results in
different numbers of data points in each bin, and
hence different levels of significance for the resulting
correlations.
Figure 5 shows trends in most of the larger data
sets that lower potency toxins have better correlation
with Ub than higher potency toxins. For the NCI
cytotoxicity and Fathead Minnow data (Fig. 5d and e
respectively) there is little trend for UB6, although for
UB5 only the highest concentration data (−3 to 0
band) shows a statistically significant correlation (i.e.
the certainty range is below 0). For all other data
sets, both UB5 and UB6 show negative correlation of
Ub with concentration (i.e. confidence limits are <0)
only for the highest concentration band. Figure 5
confirms, for these data sets, that the correlation of
UnBiological with toxicity is an effect seen primarily
in compounds that have low intrinsic toxicity.
This observation may explain the failure to observe a
correlation of Ub with toxicity in Saccharomyces. In the
data set analysed here, Saccharomyces was tested for the
effects of chemicals at six concentrations from 1.3 uM
to 100 uM. Thus no chemical with an IC50 of >100 uM
could be detected in this screen, and so the IC50 values
analysed here are all below the threshold at which a
statistically robust correlation of Ub and toxicity
would be expected.
Mechanism of Ub correlation with toxicity
The observation that a simple and non-specific measure
of chemical structure like Ub might be correlated with
toxicity is unexpected. The observation that the correl-
ation is more pronounced for weak toxins is, on the face
of it, baffling. QSAR measures of biological potency are
usually more effective for the most potent agents –
whether toxins, drugs, hormones or other effectors. The
findings in Figs. 4 and 5 therefore require a mechanistic
explanation for the correlation of Ub with toxicity that
operates at millimolar but not micromolar concentrations.
This second part of the paper, and the results shown in it,
address the plausibility of a potential mechanism.
The mechanism I propose here is that many, probably
most chemicals will interact with some, maybe many,
components of the cell at millimolar affinity.
The distinction of small molecules into ‘ligands’ and
‘non-ligands’ is a convenient classification for small mol-
ecules with respect to their effects on a specific protein,
but it is a fiction not reflected in chemical reality. It sug-
gests an absolute distinction between ‘binding sites’ and
‘non-binding’ sites. In reality, a small molecule can inter-
act with atoms across the surface of a protein, and can
often bind to proteins in more than one conformation
and at more than one site (discussed further below).
Only those sites which are unique and bind molecules
with much higher affinity than any other site are called
‘binding sites’. The reality of the other sites that can, and
do, interact weakly with small molecules is however
illustrated by experimental evolution studies, where new
protein functions are typically created by selecting
new modes of interaction between protein and ligand
from weak interactions already present in the original
protein [31].
There is a substantial body of literature that suggests
that many, maybe most small molecules can interact
with many, possibly most proteins at millimolar concen-
tration. I summarise three lines of such evidence below.
This data will be very familiar to those involved in
pharmaceutical screening programmes.
High-throughput screen data
High-throughput screening (HTS) is a common route to
discovering novel biological function in large libraries of
chemicals. In an HTS campaign, a very large library of
chemicals (tens to hundreds of thousands) is tested at
one or a few concentrations in an entirely automated
assay designed to give a simple, semi-quantitative meas-
ure of whether a chemical interacts with a specific mo-
lecular target. Compounds that reach a threshold of
activity (“hits”) are then taken on for further study. Such
large screening programmes are a common approach to
drug discovery [32].
Table 4 Structures sets used for docking
Protein PDB structural data sets used for docking
ABL 2e2b 1 m52 1iep 3k5v 3qri 3qrk 3g6g 1ab2 2g2h 2hiw
2gqg 2hz0 3cs9
Aldolase 1ald 2ald 4ald
HIV
protease
1a94 1kj4 2bpz 2qhz 2qi6 2r5p 2r5q
PDE2b4b 1f0j 1ro6 1ro9 1ror 2qyl 3frg 3gwt 3hmv 3o57
PPAR 1i7g 1kkq 2npa 2p54 2rew 2znn 3et1 3kdu
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Typical reports of such screens report a ‘hit rate’ of
between 0.1 and 1 %, and report finding ‘hits’ that
bind to the target protein with micromolar affinities
[32, 33]. Most freely available databases of the bio-
logical effects of molecules also assume that com-
pounds either bind to a target with micromolar
affinity or better, or that they do not [34]. Such data-
bases imply that ‘not binding’ at the tested concentra-
tion means not binding at all. However this literature
is misleading. More detailed reports of HTS cam-
paigns routinely report widespread “non-specific”
interaction of small molecules with protein or cellular
targets (see e.g. [35–38]). Assay conditions, screening
concentrations, detection thresholds and other factors
are tuned to achieve a hit rate of <0.1 % in what in
reality is a continuum of binding.
Usually the raw data behind an HTS screening
programme is not available – only summary statistics
and the data on the ‘hits’ is published. However the real-
ity of HTS binding can be illustrated with HTS data
available from the National Cancer Institute, which has
published detailed screening data on a library of ~47,000
compounds for anti-HIV effect and ~60,000 compounds
for anti-cancer effect [39, 40]. Figure 6 summarises this
data in terms of the chance that a compound will be
found to have a positive effect on a screen at a particular
concentration. Not all compounds are tested at higher
concentrations, so Fig. 6 plots the fraction of compounds
Fig. 4 UnBiological vs. toxicity for selected organisms. Plots of UnBiological vs. toxicity endpoints for three of the data sets analysed here. Each
dot represents the LD50 (X axis) vs Ub value (Y axis) for one compound. Ub is calculated as described in the Methods section and Appendix 2. In
summary, Ub represents the largest region on a molecule that is not present in a metabolite, as defined by a 5-atom (Ub5) or 6-atom (Ub6) overlap. a:
Ub5 vs. LD50 for Chlorella, b: Ub6 vs. LD50 for Rainbow trout, c: Ub6 vs. LD50 for Lemna, intoxicated with compounds other than herbicides
Fig. 5 Correlation of UnBiological with toxicity by potency band. Correlation of Ub5 and Ub6 with different toxicity endpoints. For each data set, the
data on a compound was binned for compounds having different EC50 or LD50 values, and the correlation of the toxicity endpoint with Ub was
correlated with the toxicity values within that concentration range. Thus for Rat oral LD50 (Panel a), toxicity was binned into Log(LD50) < −4,
Log(LD50) between −4 and −3, Log(LD50) between −3 and −2, and Log(Ld50) >−2, all values in molar. Correlations were calculated for each of these four
data sets. Error bars are 95 % confidence limits for the correlation, based on the number of data points in each bin. For all panels: X axis = concentration
bins, in log (molar). Y axis: correlation of Ub and toxicity within that data sub-set. Panels a: to f: − Rat oral toxicity, mouse oral toxicity, rat carcinogenic
potential (from CPDBAS), NCI cell line cytotoxicity, Fathead minnow toxicity and tetrahymena toxicity
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that have an effect at a concentration as a fraction of the
compounds tested at that concentration. The result is
clear. There is a continuum of affinity in this essentially
random set of chemicals for their molecular targets, and
while the chance that a compound has an effect at micro-
molar concentration is low, the chance that it has a bio-
logical effect on mammalian cells approaches 1 as the
concentration approaches 10 mM.
Fragment-based screening
Fragment-based screening (FBS) seeks to identify small
molecules that bind with relatively low affinity to pro-
teins, and then combine these into larger molecules that
bind with greater affinity (reviewed in [41–45]). FBS
actively looks for high micromolar or low millimolar
affinity of small molecules to proteins. It is a common-
place for researchers in this field that many small mole-
cules (“fragments”) bind to most proteins at low
millimolar concentrations. For example, [43] comment
that “Novice users [of fragment-based screening by
BiaCORE] are often surprised to see how often small
molecules bind indiscriminately to proteins when com-
pounds are assayed at high concentrations”. The data
they give suggests ~75 % of a 1000 compound subset of
the Maybridge Ro3 library bound equally well to two dif-
ferent targets at high micromolar to low millimolar con-
centrations. Congreve et al. [46] find that 90 % of
compounds in their library have some binding at mM
affinities. Hubbard [41] found a ‘hit’ rate of between 1.5
and 4.7 % when measuring small molecule binding to
proteins at 0.5 mM by NMR. Giannetti [47] reviewed 20
different fragment-based screens, and report that all
show ‘non-specific’ binding at affinities of 1 – 4 mM,
although the highest affinities found ranged over three
orders of magnitude in the different experiments.
Spurlino [48] found that between 5 and 50 % of a library
bound to target protein crystals at 5 mM (depending on
library/target combination).
Other Non-Specific Binding observations
Non-specific interactions are a fact of life for pharma-
ceutical researchers, even among molecules that are se-
lected for their specificity of action. Even in launched
pharmaceuticals, supposedly selected for their singular,
specific interaction with one target or target class, multi-
target interactions are being recognised as the rule ra-
ther than the exception [49, 50]. LaBella commented
“The non-specificity of drugs is a generally acknowl-
edged truism” over 20 years ago [50], with genome-scale
testing of molecules confirming that nearly all small
molecules bind to multiple proteins [51]. Such ‘non-spe-
cific effects’ now being accepted as a critical part of
drugs’ actions [52, 53]. Houk et al. review a range of
studies of binding of small molecules to proteins and cy-
clodextrin mimics of protein binding sites, and find an
average binding affinity of ~0.5 mM [54].
Molecular mechanism of low affinity binding effects
It is worthwhile touching briefly on potential mecha-
nisms of millimolar binding of compounds to proteins,
and the likelihood that this will materially affect the pro-
tein’s function. Again, we must challenge the conven-
tional model of a ligand binding to a ‘binding site’ on a
protein. Structural studies have shown that many pro-
teins can bind a diversity of chemical structures through
adaptation of their structure (reviewed in [55–57]).
Fig. 6 NCI screening data analysis. X axis: concentration. Y axis: fraction of compounds in NCI public datasets on cell-based screens that show inhibitory
effect in that assay as a fraction of number of compounds tested at that concentration. Results are binned into concentration bins on a log scale, each
bin representing log (concentration) = 0.25. Blue diamonds: HIV screening data [39]. Red squares: cell line screening for anti-cancer effect [40]
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Many proteins exist in dynamic equilibrium with
partially or completely unfolded structures, some being
dominantly disordered [58–61]. Post translational modi-
fication [62] or ligand binding [63, 64] can switch
proteins from a disordered to a more ordered state,
switches which can be related to their regulation and
function [59, 65]. Proteins can also have multiple
ordered, metastable structures (reviewed in [66]), and
different folding states can be selected by ligand binding
and have significantly different biological function (see
for example [67–71]). There can also multiple folding
paths leading to each of those states (see e.g. [72]).
A molecule that binds even weakly to one folding state
of a protein and not to another will bias the population
of protein folding states by stabilising the bound state
over the others (by definition, if a small molecule M
binds to folding state A, then the combination of A +M
must be more stable than A and M on their own, and
hence more likely to occur). If one of the structures in
the spectrum of structures has a function absent from
other structures, then binding of the small molecule will
change that function by changing the amount of the
functional conformer. The binding need not be ‘tight’,
and may not even be detectable on the canonical crystal
structure for the protein, but will nevertheless affect
function in the cell.
In conclusion, it is found in many types of experimen-
tal systems that all, or nearly all, small molecules interact
with many proteins with low millimolar affinity, and
these low affinity bindings can have significant biological
affect through modulation of the population of structures
adopted by a protein. This observation leads both to an
explanation of the mechanism of millimolar toxicity, and
to its correlation with UnBiological.
Proposed mechanism of correlation of Ub with
millimolar toxicity
Selection against protein binding of metabolites
The observations above that many molecules interact
with many cellular targets at millimolar concentration,
and that these are likely to have significant biological ef-
fects, raises an obvious question. If many molecules can
interact with many proteins at low millimolar levels, and
such interaction has adverse effects on the cell, and
many metabolites are present in the cell at low millimo-
lar concentration, then why does the cell not poison it-
self with its own metabolites?
A plausible explanation is that the proteins (and other
large molecular constituents of the cell) have evolved to
avoid interference from the cell’s normal constituents. A
protein that needs to interact with (say) an α-amino acid
will evolve a binding site for that α-amino acid. A pro-
tein that does not require interaction with an α-amino
acid for its function may nevertheless have a low affinity
binding site for an α-amino acid in one of its conformers
by chance. If this low affinity binding site has an adverse
effect on the cell, then it will be selected against. In
short, any non-specific interaction of the cell’s normal
constituents will be selected against just as there will be
positive selection for beneficial interactions.
Thus we would expect any binding site or pocket on a
protein that could bind an amino acid to be selected
against unless that interaction provided a beneficial ef-
fect on the function of the protein. Any compound that
‘looked like’ an amino acid (i.e. had similar chemical
groups arranged similarly in space) would therefore also
not find binding sites on that protein. Similarly there
would be selection against random or fortuitous binding
sites for the chemical features present in sugars, lipids,
phosphate esters and other common structures in me-
tabolism. However there would be no selection against
low affinity, random binding to flurocarbons, organosili-
con compounds or other chemicals quite different from
anything normally in a cell. These, therefore, would be
free to bind to any cellular protein if, by chance, a bind-
ing site happened to exist for them. The larger the seg-
ment of the xenobiotic that was unlike the chemistry of
life, the greater the potential affinity for such a non-
canonical binding site. The association of UnBiological
with toxicity shown in Table 1 is therefore a conse-
quence of the failure of biochemistry to be selected to
avoid random binding of chemicals that the cell does
not usually encounter.
Testing the hypothesis with molecular docking
Such a hypothesis has not been tested experimentally as
far as I know, except in so far as low affinity binding of
small molecules to proteins is commonly observed as
noted above, although it has been observed that D-
amino acids are mildly toxic to a wide range of microor-
ganisms compared to their L-enantiomers [73]. In
principle the low millimolar binding of small ligands to
proteins could be tested computationally using mo-
lecular docking software, by trying to dock molecules
known to not be ligands for a protein to that protein.
Large-scale protein docking exercises do show that
the majority of small molecules dock to target pro-
teins with low millimolar or high micromolar affinity
(for example [74–76]). Unfortunately, the low-affinity
predictions of these exercises are unreliable (which is why
they are usually ignored). As we do not know where the
‘binding site’ for a non-ligand might be, the test non-
ligand must be docked to the whole protein, This provides
such a large number of potential interactions that the soft-
ware cannot reliably discriminate actual likely binding
sites from implausible ones. Figure 7a illustrates this,
docking 56 drugs with the ABL receptor. There is a strong
trend for larger molecules to be predicted to have a higher
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affinity for ABL (which is plausible), but the largest mole-
cules are predicted to bind as tightly as some bona fide
inhibitors, despite having no known inhibitory effect on
the enzyme.
If we confine ourselves to comparing molecules of the
same size and atomic constitution, then some of the
artefactual results shown in Fig. 7a might be avoided.
Figure 7b shows the comparison of the predicted ener-
gies of binding of α-amino acids compared to β-amino
acids to five mammalian proteins, selected to represent a
mix of functional classes of proteins for which multiple
structures and many authentic ligands were known. α-
amino acids are core metabolites in mammals, β-amino
acids are not part of normal mammalian metabolism
with a couple of exceptions. For some but not all pro-
teins tested, α-amino acids are predicted to bind with
lower affinity than β-amino acids, as predicted by the
hypothesis. The exceptions found here are HIV protease
(which would be expected to bind amino acids, as they
are related to its substrate) and PPAR-γ (for which I
Fig. 7 Docking small molecules with entire protein structures. a. Binding of 18 known ABL inhibitors, compared to the binding of 56 drugs or natural
products not reported to have any effect on ABL kinase activity. Y axis: Vina output binding energy. X axis: molecular weight. b. Comparison of the
predicted binding energy of 15 alpha amino acid and their alpha-N methyl alpha-carboxymethyl derivatives with the binding energy of equivalent
beta amino acids and amino acid derivatives to ABL, Aldolase, HIV protease, PDE2b4b and PPAR gamma structures.. Excluded amino acids were: Glycine,
which has no beta amino acid, beta alanine which is a metabolite in its own right and so was excluded, beta aspartate and asparagine which are the
same as alpha aspartate and asparagines, and beta threonine which is likely to be unstable and so not a realistic chemical structure. Error bars are 95 %
confidence limits (1.98*standard error of the mean)
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have no explanation). Repeating this exercise with more
sophisticated models that took the dynamics of proteins
as well as ligands into account (e.g. [77, 78]) might pro-
duce more useful results.
Conflict with pharmaceutical experience
The suggestion that molecules that are not like biological
molecules are more likely to be toxic appears paradoxical
to the pharmaceutical chemist, as many drugs have potent
(and hence potentially toxic) effects precisely because they
are close molecular mimics of known metabolites. Thus,
steroid drugs are potent precisely because they mimic
natural steroids, dideoxyribonucleotides block viral
DNA synthesis because of their mimicry of normal
nucleosides [79, 80], penicillins mimic peptidoglycan
components [81], and so on. However these molecules
have been selected by evolution or by chemists to both
mimic a specific biological effector and not to have any
other effects than their target pharmacology. It is a truism
of drug discovery that achieving this combination is ex-
tremely hard, and that unexpected or ‘off-target’ effects
are a common cause of failure in drug discovery and de-
velopment programmes [82–84]. Some of these effects are
due to the close structural similarity between members of
families of proteins, so that a drug selected to bind with
high affinity to one target will be likely to bind to another,
structurally similar target. However other ‘off-target’ ef-
fects are not obviously related to the known structural
similarity of the ‘off-target’ proteins [85]. Yamanishi et al.
[86] suggest that this is because small regions (equivalent
to the Fragments used in my analysis) confer protein bind-
ing. A substantial fraction of the effort in drug discovery
programmes is tailoring the specificity of the candidate
drug to bind to a small number of targets, and many
launched drugs actually bind to more than one protein
family [87–90]. Drugs are therefore a special case, the re-
sult of extensive selection by man to fit with biology. The
same explanation is true for the observation that chemi-
cals that are not metabolites but fall within ‘Biochemical
Space’ have a higher chance of being toxic even in the
absence of selected pharmacology [4].
Detoxification and resistance
A second apparent conflict with pharmaceutical experi-
ence is that organisms can and do tolerate a wide range
of compounds that are toxic through tolerance, detoxifi-
cation, and resistance mechanisms. The first two of
these are less important to my general thesis than they
might appear, and the third actually supports it.
Tolerance to a toxin or drug is almost invariably
caused by changes in the organism’s physiology to com-
pensate for the action of the drug or toxin. This is clas-
sically true of pharmacological agents such as alcohol,
nicotine or heroin, but also to classic toxins such as
arsenic. Mechanisms that oppose the effect of the drug
or toxin are induced to restore a more normal physio-
logical state. This is unrelated to the mechanism of
intoxication in the first place.
Detoxification is a broad approach to removing toxins
from an organism. It usually relies on enzymes (such as the
CYPs in mammalian liver [91]) or transporters (such as the
PGP family [92]) with very broad substrate specificities. It
can also involve physical separation of the toxin into a de-
fensive cell compartment. Compartmentalization is a com-
mon strategy for cells to sequester damaging metabolic
chemistry from cell components that that chemistry might
damage (e.g. oxidative phosphorylation in eukaryotes, ana-
mox in prokaryotes). Sequestering misfolded proteins, dam-
aged cell components or toxins can be seen as a form of
‘internal exile’, analogous to the export of these materials.
Acquisition of resistance be through one of two broad
mechanisms. Detoxification mechanisms can be in-
creased, often by mutation that increases expression of
the relevant protein – this is a common mechanism of
acquisition of drug resistance in cancer cells and in bac-
teria ([92, 93]. The other mechanism is for targets of the
toxin to mutate so that they no longer bind the toxin.
This is common for drug resistance [94–96]. It is not ex-
pected to apply to low potency, low molecular weight
toxins, because (following my argument above) many,
possibly most proteins would have to be mutated to
evade toxicity. The mechanism of organisms’ resistance
to chemicals other than drugs has not been reviewed
systematically, so we do not know if this prediction is
true.
Conclusion
I have shown above that molecules that contain seg-
ments that are not similar to common components of
metabolism are more likely to show toxicity at millimo-
lar levels than compounds that have chemistry similar to
life. I relate this to the widespread observation that many
chemicals bind to many proteins at low millimolar
levels, and that this can materially affect the function of
those proteins.
This observation is an explanation for the observation
that the chemistry of life occupies a small corner of the
chemical space. In order to function, the components of
the cell must interact with each other appropriately, both
with functional interactions between the macro-molecules
and metabolites of the cell and with the absence of un-
wanted interactions. Each new chemical added to metab-
olism requires adaptation of the whole proteome to
accommodate the new chemical. Once a complex, self-
perpetuating metabolism has evolved, adding to it will be
an increasingly demanding evolutionary task, not an im-
possible one but one that the pragmatic mechanisms of
evolution will tend to avoid.
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This finding has two implications. Firstly, UnBiologi-
cal could be used as a measure of the chance that a
new molecule is toxic. Such broad toxicity predictions
are less useful than predictions of specific mecha-
nisms of toxicity, and UnBiological specifically does
not provide a mechanistic explanation. It is also only
as statistical estimate. From the data analysed here,
Ub5 or Ub6 could be used to give an order-of-
magnitude estimate of the potency of a low-potency
toxin, but would say nothing about high potency tox-
icity. It is possible that coupling Ub with other measures
[4] might give more accurate estimates. As an initial screen
for ‘drug-like’ properties [97–100], however, such a statis-
tical indicator could find a use.
In this application of predicting toxicity, a strong limi-
tation of the analysis presented here is that it takes no
account of the concentration of metabolites in the cell.
Metabolic intermediates present at nanomolar concen-
tration are given the same weight in the Ub calculations
above as common components such as glucose or gly-
cine. One would however expect the selective pressure
on proteins to avoid binding glucose to be much stron-
ger than the pressure to avoid binding metabolites
present at nanomolar concentrations.
An extension of this work would therefore include
a concentration term in the calculation of UnBiologi-
cal. This would include two components – consider-
ation of the differing metabolomes of different cells
or organisms, and quantitative consideration of the
concentration of metabolites in an organism. In this
study, a single collection of metabolites (“core metab-
olism”) was used to define UnBiological. I expect that
predictions of toxicity based on the actual intracellu-
lar metabolome of a specific species would be more
accurate for that species (and less accurate for other
species) than this generic approach. This is however a
substantial undertaking, involving re-calculation of
most of the comparisons presented here for each spe-
cies, and so has not been attempted in this paper: my
goal here is to show that this approach is theoretic-
ally and practically interesting. It might also be valu-
able to weight the contributions of metabolies to the
Ub calculation according to their intracellular concen-
tration, although this is fraught with difficulty as
intracellular concentrations of metabolites are very
hard to measure, and in any case are modulated by
the protein binding that this study postulates occurs
promiscuously and universally. Future work could also
explore the size of the overlap necessary to define
Ub: again, this would be doable, but time-consuming,
and so has been left for future work.
The second implication of this work is in the field
of metabolic engineering and synthetic biology. Engin-
eering an organism to produce a new chemical or
execute a new metabolic pathway has been thought
to require the expression of suitable enzymes to make
the chemical and any intermediate or precursor mole-
cules at sufficient concentration, efficiency, and from
suitable feedstock. The rest of the cellular machinery
is generally viewed as a ‘chassis’ on which to attach
these changes [101–103]. For chemicals or gene prod-
ucts produced at low concentrations this is likely to
be true [104]. However if the goal of the engineering
is to produce a chemical at substantial levels [105],
then the analysis in this paper suggests that many as-
pects of the cell must be engineered, especially if the
chemical to be produced is very different from one
usually present in the cell.
Methods
Toxicity data
Databases of molecular structures and biological end-
points were collected from literature sources, as listed in
Table 3. Data was filtered to collect toxicity endpoints
that were, as far as practical, the same endpoint for
different studies on the same organism. Data sets were
collected that
 provided a quantitative half-effect concentration
estimates (i.e. not single concentration toxicities)
 provided data on at least 50 compounds from
diverse chemical families
 were available from a small number of sources
(for practical reasons, data sets of 200 compounds
studied in 200 papers were not used)
 were from species with recognised use in toxicity
testing.
All EC50 values were as reported in the relevant
papers or databases except those for Saccharomyces
cereviseae, where EC50 values were calculated from
the raw inhibition data downloaded from [106]. The
Saccharomyces data set was filtered to exclude or-
ganometallic compounds, to exclude mixtures or salts
other than halogen or alkali metal salts, compounds
for which growth inhibition at the highest concentra-
tion was <50 % or for which the growth inhibition at
the lowest concentration was >50 %, and compounds
for which the range of calculated EC50s across the 13
strains tested in this data set (calculated as [maximu-
m(EC50)-minimum(EC50)]/average (EC50)) was >1. The
resulting data set represented well defined organic com-
pounds with EC50s within the experimentally measured
concentrations and consistent toxicity across a range of
Saccharomyces cereviseae strains.
Chemical structures were collected as. MOL files, and
compiled into an SDF file for processing.
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Molecules of metabolism
The chemical space of metabolism was taken as all
the molecules shown on the printed version of Part A
(intermediary metabolism) of the Roche/Expasy meta-
bolic chart, with the exception of the steroid hor-
mones. Steroid hormones were omitted because they
represent many elaborations on the same core (sterol)
structure, and do not add significantly to the diversity
of chemical types. The chemical space of 611 metabo-
lites is referred to as ‘core metabolism’ in this paper.
Generation of ‘all’ molecules in chemical space
The space of all possible chemical structures was
explored by the program Combimol [5]. In brief, the
program generates chemical structures based on
SMILES strings [107]. The program aims to generate all
the molecules of a specified size (defined as number of
non-hydrogen atoms), using a subset of C, N, O, S, P or
Si that is specified by the user. ‘All molecules’ are here
defined as all 2-D chemical structures that have a bond-
ing pattern consistent with the valencies of the atoms
used: four bonds for C and Si, 3 for N, 2 for O, 3 or 5
for P, 2, 4 or 6 for S. For the work described in this
paper, silicon was excluded from this list, and only P(V)
and S(II) and S(VI) (sulphate) were used, consistent with
those elements’ use in metabolism.
The SMILES language is a simple, text-based method
for coding chemical structures [107]. The program starts
by generating an exhaustive list of all possible linear
atom strings up to the desired size: if the maximum size
was 4, it would generate CC, CCC, CCCC, CCCN,
CCCO, CCCP, CCNC etc.. It then replaces single bonds
with double bonds in any position allowed by the ele-
ments (CCC =C, CC =CC etc.). It then generates cyclised
versions of these strings (C1CCC1, where the two ‘1’ sym-
bols represent atoms that are connected – the reader is di-
rected to [107] for a further description of the SMILES
language). A molecule can have up to two ring systems,
including fused rings. These form unbranched ‘core’ mole-
cules. In a final step, the ‘core’ molecules are joined to
each other to form branched molecules: thus CCC and
CC could be joined to form CC(C)C.
A number of rules are included in this process to
remove atom combinations that would be unstable (such
as COOOC).
As described in [5] the program is not completely
exhaustive (it under-represents quaternary carbon cen-
tres, for example): however I estimate that it generates
over 90 % of the molecular structures that are consistent
with the rules set provided. The program, and a new,
more systematic version, which was not used in this
work but will be for future work, is available for non-
commercial applications from the author.
Molecular matching and similarity
I define here the terms for molecular structures and
matching used in this paper. These are not significantly
different from how these terms are used in the general
chemical literature, but are laid out explicitly here to
avoid confusion.
 A molecule is a set of atoms connected by bonds, in
which all the atoms’ valencies are filled. It is
assumed that all valencies that are not explicitly
linked to another atom in the description of the
molecule are filled with hydrogen atoms.
(“molecule” here is completely consistent with the
common understanding of the term, and so will not
be capitalised: I define it here solely for
completeness).
 A Fragment is a set of atoms connected by
bonds, in which the valencies of at least one of
the atoms are not filled. A Fragment therefore
represents part of the structure of a molecule,
and not a real physical entity.
 Substructure. Molecule or Fragment A was said to
be a substructure of molecule or Fragment B when
all of the non-hydrogen atoms and all the bonds of
molecule or Fragment A could be overlaid on mol-
ecule B in at least one position.
 Overlap. Molecule or Fragment A and molecule or
Fragment B are said to have an N-atom overlap
when the largest Fragment which is a substructure
of molecule A and of molecule B has N atoms.
To identify matches and Overlaps between mole-
cules and Fragments, I used a 2D fragment-based mo-
lecular descriptor system that has previously been
described [7, 8], and proven effective in building
models to predict toxicity outcomes. In summary, I
generate an exhaustive set of Fragments from all the
molecules used in this study as follows. For each pair
of molecules, the maximum common structure (Max-
imum Common Subgraph – MCS) is found by ‘over-
lapping’ the 2D molecular structure. The MCS
between each of these Fragments and between each
Fragment and each original molecule is then com-
puted to generate further Fragments. This is repeated
until no new Fragments are found. The result is a list
of all the molecular Fragments that are present in
two or more of the molecules in the set. Fragments
of 1 or 2 atoms are ignored.
Molecular descriptors of a molecule are then com-
puted by matching a set of these molecular Fragments
to that molecule, and counting the number of distinct
ways that a Fragment can be exactly mapped onto a
molecule. A descriptor is an integral count of the num-
ber of occurrences of a Fragment in a molecule. The
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molecule as a whole is described by the pattern of
Fragment descriptors.
Molecular matching and molecular Fragment gener-
ation were performed by software build by Amedis
Pharmaceuticals Ltd. (see [7, 8] for details) and kindly
provided by Dr. Antranig Basman. Conversion of data
files for transfer between programs was done with a
number of small programs written specifically for this
project in Qbasic, and compiled with the QB64 com-
piler [108]. All programs other than MolDescrip are
available from the author on request, and source code
for programs other than those originating from Ame-
dis Pharmaceuticals are also available. General chem-
ical database manipulation was done using the
CambridgeSoft ChemBioOffice suite version 12.0,
under site licence to MIT. All work was done on
standard PCs running various versions of Windows
depending on their age.
Docking
Docking was done using AutoDock Vina [109]. The
‘binding site’ was defined as the entire surface of the
protein for all the proteins. Potential ligands were
docked to a number of structures for each protein, as
listed in Table 4. Ligands were docked using default pa-
rameters except for ‘Exhaustiveness’, which was set =
100. The binding energy of a ligand to a protein was
taken as the maximum (most negative) binding energy
of any ligand conformation to any site on any of the
tested protein structures.
Calculation of ‘Unbiological (Ub)
‘Unbiological’ is a measure of the size of a region of a
molecule that is not represented in metabolism. In this
paper ‘metabolism’ is taken to be the set of ‘core metab-
olism’ molecules defined by the 611 chemicals listed in
the Roche/Expasy metabolic map, as described above
(section Molecules of metabolism).
What is meant by ‘not represented’ depends on the
size of the Fragment that is being considered. If we only
require one atom similarity between a metabolite and a
test molecule, then clearly almost all molecules can
‘match’ a core metabolite. Thus Ub depends on our def-
inition of similarity.
In this study, I define Ub as follows: Fig. 3 illus-
trates this process. The metabolites of ‘core metabol-
ism’ are broken into N-atom fragments. A region is
‘unbiological’ if it does not contain an exact match to
any of the fragments generated from core metabolism.
Thus in Fig. 3, three metabolites (top left) and three
test chemicals (top right) generate 12 Fragments, of
which 9 (bottom left) completely match the original
metabolites. The three Fragments not found in me-
tabolites (bottom right) are UnBiological. These are
matched to the target molecules (bottom right). The
size of the largest UnBiological fragment that can be
matched to a test molecule is its Ub value.
This is a measure of the size of a sub-region of a mol-
ecule that has an arrangement of atoms unlike an ar-
rangement found in biology.
As noted in the text, this depends on the original set
of biochemicals used as a definition of ‘biochemistry’.
The use of central metabolic pathways is convenient, but
could be improved.
Ethics and consent
This work involved no human or animal experimen-
tation, and so no ethical or other consent was
relevant.
Availability of data and materials
The complete data set of Ub values, toxicity endpoints
for the chemicals analysed in this study is available for
download from LabArchives (https://mynotebook.la-
barchives.com/), at DOI 10.6070/H4VQ30PJ (direct URL
for download of the spreadsheet https://mynotebook.la-
barchives.com/share_attachment/Bains_Data/MTkuNX
wxNTAzOTUvMTUtMy9UcmVlTm9kZS83NjQwNTkx
NDl8NDkuNQ==). A ZIP file of the MOL files for rhe




used for this specific analysis were proprietary to Amedis
Pharmaceuticals Ltd (Cambridge, UK), when that
company existed, and are available as compiled code only:
consequently they are not available for general use. How-
ever similar chemical matching functionality can be found
in RDKit, (http://www.rdkit.org/docs/index.html), which
is an open-source, Python based platform.
Endnotes
1No hits for searches for this structure in the Dictionary
of Natural products.
2There were not enough compounds in the wider set
to make any statistical conclusion on the correlation, so
it is not included in Table 2.
Appendices
Appendix 1: Method for calculating the likelihood that a
random sampling of a chemical space will contain a
specified substructure of specified size
Random sampling of chemical space
The likelihood that a set of molecules M contains
at least one target molecule T containing the
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substructure S is not simple to estimate, for four
reasons.
Firstly, some substructures are much more abun-
dant in a ‘random’ chemical space than others. The
structure C-C can be linked to 6 other atoms, in
molecules ranging from C2H6 up in size. The struc-
ture C≡N can only be linked to one other atom, even
though it has the same number of non-hydrogen
atoms. Thus CC is going to lead to more structural
possibilities than C≡N, and hence occur more fre-
quently. The relative abundances of different sub-
structures are hard to predict ab initio.
Secondly, substructures are not independent, and so
two examples of S in M cannot be treated as inde-
pendent events. For example, if we find the structure
C=C-N-C in M, our expectation that we also find C-
N-C-C is higher than if we do not find C=C-N-C,
because the two substructures overlap.
The probabilities of finding a specific substructure
is also dependent on the atoms and bond types used
to construct the chemical space to be explored. Find-
ing N-N is more likely in a chemical space that con-
tains hydrazines.
Lastly, the maximum number of fragments S that
could match T is AT-AS, where AT is the size of T
and AS is the size of S. However it might be less than
this, due to symmetry and duplication within T. For
example, cyclooctane only matches the three-atom
fragment C-C-C, and no other three-atom fragment.
These multiple, interrelated contingencies lead me
to estimate the chances of finding S in M empirically
by simulation. I generated a large set of molecules
generated using Combimol under the same rules as
described in the main text. From this I selected a
random subset M (random subsets were selected
using the Excel RAND () function). Sets M of 50,
200, 611 and 2000 molecules of 7, 14 and 21 non-H
atoms were probed with the fragment sets of 3, 4, 5
and 6 atoms, using the same approach as in Fig. 2 of the
main paper. Multiple runs of the Fragment set against dif-
ferent, randomly selected M were run, and average and
standard deviation of the number of S not found were re-
corded. The results are shown in Table 5.
We can seek an empirical model for the fraction of
the set of all fragments of size AF that are not found
in a set of molecules M of whose geometric mean
size (measured in number of non-hydrogen atoms) is
AM and containing NM molecules. I define this frac-
tion as Fragments Not Found (FNF). Inspired by the
similarity of the curves of FNF vs NM to the curves
of enzymes reaction rates following Michaelis Menten
kinetics, I find that the numbers in Table 5 are roughly
modelled by








Where AF = number of atoms in the fragments, NM =
number of molecules in M, AM=geometric mean of the
size of molecules in M. The exponential in AF and AF
2 is
expected from the equations for the numbers of mole-
cules in an organic chemical space as a function of
molecular size [5].
We can use Eq. 1 to predict how many fragments
would not match a set of chemicals with the same
size distribution as the molecules in the central, pri-
mary metabolism of life, described in [110] and
shown in Fig. 8. These are the “Control” frequencies
of un-detected fragments shown in Fig. 2.
Appendix 2: Detailed description of the method and
software used to calculate the ‘UnBiological’ parameter
Calculation of UnBiological (Ub)
The following is a description of how the UnBiologi-
cal (Ub) measure was generated. Note that this is not
the most efficient way of generating this parameter
that could be defined, but it uses the software avail-
able. I strongly suggest that any researchers who wish
to replicate and extend this work develop their own
Table 5 Modelled expectations of fragment matching to sets of chemicals
AM 7 atoms 14 atoms 21 atoms
AF NF NM 50 200 611 2000 50 200 611 2000 50 200 611 2000
3 62 0.356 0.177 0.076 0.024 0.292 0.136 0.041 0.019 0.245 0.084 0.048 0.012
4 318 0.571 0.273 0.101 0.021 0.465 0.202 0.063 0.022 0.356 0.127 0.039 0.011
5 1363 0.832 0.561 0.321 0.119 0.702 0.448 0.240 0.092 0.611 0.335 0.164 0.064
6 9240 0.975 0.904 0.771 0.529 0.899 0.760 0.581 n/m 0.852 0.674 0.476 n/m
AF – number of (non-hydrogen) atoms in the fragment set. NF – number of fragments in the chemical space containing AF atoms. NM – number of test molecules
in the test set. AM – number of atoms in the molecules in the test set. Cells show the fraction of Fragments that are not found in at least one of the Molecules in
the test set. n/m = not modelled
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software using an open-source code base like RDKit,
whose internal functioning is accessible.
Software used is:
 FRAGGEN. Inputs a set of. MOL files and outputs
a set of MOL files containing all the Fragments
that can be generated from the input files that
match at least two of the input molecules. A
‘Fragment’ in this regard is a connected group of
atoms that is common to at least two of the
molecules in the input data set.
 MOLDESCRIP. Inputs a parameter file, a set of
Fragment MOL files as descriptors, and a set of
target MOL files as targets. Identifies all the
matches where a Fragment overlaps a target
MOL file.
 Conversion files, to convert input and output
files from FRAGGEN and MOLDESCRIP into
forms usable for this project.
Steps performed.
1. Generate all the Fragments of metabolites by
running FRAGGEN on the set of molecules in
the ExPasy database. This is the set of Fragments
MetabFrags.
2. Generate all the Fragments of the molecules to
be tested, by running FRAGGEN on those
molecules. This is the set of Fragments AllFrags.
(The set of ‘all molecules’ should include the
metabolites)
3. Sort the MetabFrags by size.
4. Repeat the following steps for each class of
MetabFrags having MM atoms:
4.1 Find the AllFrags fragments that have no
MetabFrag Fragments that overlap them, by
running MOLDESCRIP with MetabFrag
descriptors and AllFrag targets. This generates
a list of Fragments from AllFrags that have no
overlap with a metabolite of MM atoms
4.2 Sort these by size. This gives sets of AllFrag
Fragments that a) have no overlap with
metabolites of size MM and b) are size AA.
4.3 For each of these:
4.3.1Find whether each fragment is present in
the target set of molecules, by running
MOLDESCRIP with the selected set of
AllFrag fragments as descriptors and the
set of target molecules as targets.
4.3.2 Any molecule with a match to a fragment that
a) has no overlap with metabolites of size MM
and b) is size AA has a Ub score of ≥ AA.
4.4 Repeat for increasing values of AA until 95 %
of the target molecules are covered.
In this paper, all transfers between programs and data
reformatting was performed manually. An alternative ap-
proach would be to directly search for overlap of each of
AllFrags with all of the Metabolites to find AllFrags that
are UnBiological. This is impractical with the software to
hand, as there are >30,000 AllFrags, and MOLDESCRIP
generates inconsistent output file formats with more
than ~4000 descriptors.
Fig. 8 Size distribution of the molecules in the ExPasy/Roche biochemicals pathway map of central metabolism [10]
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Table 6 Summary statistics on the toxicity and UnBiological values for different biological endpoints
Endpoint Number Correlation with Toxicity Endpoint distribution (log molar) Ub5 distribution Ub6 distribution
Ub5 Ub6 mean median Std. dev skew max min mean median St. Dev skew max min mean median St. Dev. skew max min
Trout 24 h 186 -0.230 ** -0.337 *** -5.73 -5.64 1.39 -0.14 -0.99 -10.04 7.58 7 1.92 0.01 11 2 8.94 9 1.91 -0.74 12 2
Trout 96 h 181 -0.419 *** -0.516 *** -5.73 -5.78 1.77 0.76 -0.23 -10.88 7.58 7 1.94 0.01 11 2 8.94 9 1.92 -0.76 12 2
Pteronarcys (24 h) 52 -0.433 ** -0.385 ** -6.25 -6.83 1.27 0.75 -3.24 -7.98 8.52 8 1.70 0.15 11 6 9.71 10 1.60 -0.37 12 6
Pteronarcys (96 h) 52 -0.456 *** -0.369 ** -7.08 -7.58 1.44 0.61 -3.71 -9.55 8.44 8 1.67 0.22 11 6 9.65 10 1.58 -0.29 12 6
Bluegill (24 h) 157 -0.149 -0.215 ** -5.71 -5.63 1.41 -0.21 -2.31 -9.61 7.92 8 1.82 0.22 11 4 9.30 9 1.65 -0.28 12 4
Bluegill (96 h) 172 -0.216 ** -0.276 *** -5.88 -5.84 1.48 -0.16 -2.31 -10.20 7.85 8 1.82 0.23 11 4 9.23 9 1.70 -0.33 12 4
Gammarus (24 h) 113 -0.437 *** -0.208 * -6.17 -6.35 1.46 -0.16 -3.52 -10.73 8.19 8 1.71 0.43 11 6 9.64 10 1.46 -0.16 12 6
Gammarus (96 h) 132 -0.407 *** -0.205 * -6.56 -6.66 1.63 -0.12 -3.20 -10.82 8.14 8 1.71 0.46 11 6 9.57 9 1.47 -0.12 12 6
Fathead minnow 578 -0.311 *** -0.308 *** -3.83 -3.82 1.38 -0.15 -0.04 -9.38 5.59 5 1.41 1.07 11 2 7.07 7 1.75 0.19 12 2
Rat oral 814 -0.441 *** -0.372 *** -2.40 -2.27 0.91 -0.99 -0.43 -6.98 6.57 6 1.64 0.40 11 2 8.11 9 2.14 -0.34 12 2
Mouse oral 398 -0.199 *** -0.191 *** -2.56 -2.47 0.82 -1.30 -0.65 -6.34 6.96 7 1.43 -0.02 11 2 8.80 9 1.86 -0.57 12 2
Rat IP 170 -0.214 ** -0.147 -3.03 -2.88 0.86 -0.66 -0.90 -5.61 6.85 7 1.35 0.24 11 3 8.64 9 1.71 -0.31 12 3
Mouse IP 290 -0.180 ** -0.161 ** -3.21 -3.02 1.04 -0.93 -0.99 -7.50 6.85 7 1.45 -0.09 11 2 8.50 9 1.98 -0.46 12 2
AMES 163 -0.316 *** -0.518 *** -4.72 -4.25 1.67 -0.51 -1.52 -9.88 6.33 7 1.33 0.07 11 2 8.40 9 2.09 -0.49 12 2
CPDBAS rat 519 -0.198 *** -0.191 *** -4.18 -4.19 1.42 -0.24 -0.47 -9.85 6.36 6 1.35 -0.09 11 2 8.03 8 2.08 -0.23 12 2
CPDBAS mouse 402 -0.145 ** -0.198 *** -3.62 -3.54 1.18 -0.60 -0.53 -9.32 6.19 6 1.43 -0.18 10 2 7.85 8 2.21 -0.32 12 2
CPDBAS hamster 44 -0.430 ** -0.351 * -4.46 -4.53 0.99 0.43 -1.89 -6.05 5.95 6 1.51 -0.64 9 2 7.32 8 2.43 -0.17 12 2
Drosophila 139 -0.397 *** -0.337 *** -1.43 -1.29 0.94 -0.82 0.23 -4.80 5.82 6 1.35 0.17 10 2 7.32 7 2.07 0.00 12 2
Lemna - non-Herbicides 149 -0.428 *** -0.502 *** -4.85 -5.12 1.47 0.85 -0.24 -8.20 7.01 7 1.50 -0.37 11 2 8.68 9 1.94 -0.87 12 2
Lemna - Herbicides 174 -0.392 *** -0.428 *** -6.21 -6.08 1.65 -0.19 -2.99 -10.23 8.02 8 1.63 0.27 11 4 9.56 9 1.77 -0.02 12 4
Tetrahymena 334 -0.408 *** -0.448 *** -3.51 -3.59 0.97 0.10 -1.07 -5.82 5.62 5.5 1.03 -0.01 8 2 7.16 7 1.55 -0.11 12 2
Chlorella 91 -0.578 *** -0.738 *** -2.86 -3.16 1.47 0.43 1.06 -6.10 6.15 6 1.74 0.86 11 2 7.62 7 1.77 -0.43 11 2
Scenedesmus 63 -0.237 -0.467 *** -5.80 -5.90 1.61 1.24 0.10 -8.04 6.27 6 1.15 0.10 9 3 8.17 9 1.53 -0.92 11 3
Yeast 253 0.095 -0.014 -4.69 -4.56 0.44 -0.61 -4.01 -5.77 6.76 7 1.02 0.01 10 4 8.96 9 1.42 -0.01 12 5
NCI 768 -0.113 ** -0.137 *** -5.03 -4.67 1.38 -1.19 -2.03 -10.02 7.04 7 1.07 0.81 11 4 9.14 9 1.33 -0.20 12 5
Appendix 3: Statistics on the distribution of UB5 and Ub6 and toxicity endpoints for all the data sets analysed in this study, together with a short commentary












Table 6 Summary statistics on the toxicity and UnBiological values for different biological endpoints (Continued)
HERG 229 -0.062 0.179 ** -5.50 -5.42 1.27 -0.09 -2.36 -8.59 7.14 7 1.01 -0.14 10 4 9.67 9 1.29 -0.03 12 5
Oestrogenic 131 -0.024 -0.342 *** -5.62 -5.32 1.78 -0.47 -2.52 -9.65 6.16 6 0.95 0.49 10 4 8.97 9 1.24 -0.06 12 6
Tadpole narcosis 141 -0.043 -0.267 ** -2.47 -2.37 1.15 -0.32 -0.19 -5.33 5.01 5 1.32 0.82 10 2 6.16 6 1.82 0.48 11 2
COX-2 107 -0.069 -0.149 -6.36 -6.52 1.51 0.48 -3.00 -8.70 7.72 8 0.56 0.36 10 7 9.20 9 0.68 -0.08 11 8
Antihistamine 61 -0.097 -0.0126 -7.99 -8.13 1.27 0.84 -4.05 -10.59 6.92 7 0.76 0.61 9 6 10.2 10 1.26 -0.23 12 7
Left column, biological endpoints correlated in this study. Column 2 – number of molecules in the data set for that endpoint. Columns 3 and 4, correlation of the endpoint with UnBiological measures Ub5 and Ub6, as
per Table 3. The rest of the table lists summary statistics on the toxicity endpoints (all in Moles/lirte for solution studies, moles/kg for animal studies), Ub5 or Ub6. Listed are mean, median, Standard deviation (St.
Dev.), Skew (a measure of the asymmetry of the data - positive skewness indicates a distribution with an asymmetric tail extending toward more positive values, negative skewness indicates a distribution with an
asymmetric tail extending toward more negative values), and maximum (max) and minimum (min) values
The maximum and minimum values in each column are underlined for ease of comparison. There are more minimum values for the biological endpoint in the pharmacologically defined endpoints Cox-2 and
antihistamine, as would be expected as these molecules have been selected specifically for pharmacological potency (i.e. for low EC50 values). The molecular set used for Tadpole Narcosis has more minimum values
for Ub5 and Ub6 statistics than might be expected by chance, suggesting that the set of molecules tested for narcosis induction in tadpoles is biased with respect to the other sets used in this study. Other sets are
generally not obviously different from each other, and specifically the Ub5 and Ub6 statistics for HERG, Oestrogenic potential. COX-2 inhibition and Antihistamine efficacy appear be broadly similar to the Ub5 and Ub6
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